我們已在上線！進一步了解

Delcath Systems

DCTH

市值 US$4.89億

14.08 USD

-0.73

4.93%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

13.99

-0.09

0.64%

1天

-4.93%

5天

-8.33%

1個月

-13.19%

3個月

9.57%

6個月

30.01%

今年迄今

41.51%

1年

13.92%

5年

46.51%

10年

83.81%

關於： Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

員工： 156

醫療保健醫療器材

新聞

正面

中性

負面

市場情緒 3個月

正面 57.9%

中性 36.8%

負面 5.3%

3 Emerging Biotech Stocks With Significant Upside Potential

Biotech and specialty health care stocks can be attractive speculations because product innovation can drive explosive growth and attract intense takeover interest from large pharmaceutical companies. The challenge is determining which ones justify the risk, because early-stage drug developers are numerous, and many remain cash-burning for years.

3 Emerging Biotech Stocks With Significant Upside Potential

Zacks Investment Research

Are Medical Stocks Lagging Delcath Systems (DCTH) This Year?

Here is how Delcath Systems, Inc. (DCTH) and Encompass Health (EHC) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Delcath Systems (DCTH) This Year?

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to four individuals whose employment commenced in either July 2026 or August 2026. The grants, in the form of Restricted Stock Units (RSUs), totaled 34,00.

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

Keep Portfolio Volatility in Check With VLO, PBF, FET & DCTH

VLO, PBF, FET and DCTH screen as low-beta picks as volatility rises, backed by refining, energy-equipment and liver-cancer growth drivers.

Keep Portfolio Volatility in Check With VLO, PBF, FET & DCTH

Zacks Investment Research

5 Stocks With Recent Price Strength Buoyed by a Strong August

EDRY, RCMT, ASMB, DCTH and NESR show strong recent price momentum after a strong August, backed by improving earnings expectations.

5 Stocks With Recent Price Strength Buoyed by a Strong August

Delcath Systems to Participate in Upcoming Investor Conferences

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following investor conferences:Wells Fargo Healthcare Conference on Thursday, September 10, 2026, in Boston, MAH.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 15, 2026, in New York, NYAbout Delcath Systems, Inc., HEPZATO KIT and CHEMO.

Delcath Systems to Participate in Upcoming Investor Conferences

Zacks Investment Research

What Makes Delcath Systems, Inc. (DCTH) a Strong Momentum Stock: Buy Now?

Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Delcath Systems, Inc. (DCTH) a Strong Momentum Stock: Buy Now?

Zacks Investment Research

Recent Price Trend in Delcath Systems (DCTH) is Your Friend, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Delcath Systems (DCTH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Recent Price Trend in Delcath Systems (DCTH) is Your Friend, Here's Why

Zacks Investment Research

Wall Street Analysts Believe Delcath Systems (DCTH) Could Rally 52.44%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 52.4% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Delcath Systems (DCTH) Could Rally 52.44%: Here's is How to Trade

Zacks Investment Research

Delcath Systems (DCTH) Is a Great Choice for 'Trend' Investors, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Delcath Systems (DCTH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Delcath Systems (DCTH) Is a Great Choice for 'Trend' Investors, Here's Why

查看新聞排名

價格圖表採用Lightweight Charts™實作